Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
This study has been completed.
Study NCT00003970 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Small Intestine Cancer
Additional conditions recognized in this trial
Duodenal Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Duodenal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Ileal Diseases
Immune System Diseases
Immunoproliferative Disorders
Intestinal Diseases
Jejunal Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Interventions listed in this trial
irinotecan hydrochloride
mutation analysis
Additional drug interventions recognized in this trial
Camptothecin
Irinotecan
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
University of Chicago
National Cancer Institute (NCI)
Back to top of Main Content
